RT Journal Article
SR Electronic
A1 Bittner, Dennis
T1 New Approaches Required in Drug Development Process for Antidepressants
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 11
SP 17
OP 18
DO 10.1177/1559897715593716
UL http://mdc.sagepub.com/content/15/11/17.abstract
AB Florian Holsboer, director of the Max-Planck Institute for Psychiatry for 25 years, called for a reengineering of the drug development process for antidepressants, meaning a shift from a focus on blockbuster drugs capable of treating all depression to use of biomarkers to target subsets of patients based on disease etiology.